Phase I Trial Using Patupilone (Epothilone B) and Concurrent Radiotherapy for Central Nervous System Malignancies

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 4, 2010, Pages 1009-1016

  Fogh, Shannon ^a   Machtay, Mitchell ^a   Werner Wasik, Maria ^a   Curran Jr , Walter J ^a   Bonanni, Roseann ^a   Axelrod, Rita ^a   Andrews, David ^a   Dicker, Adam P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

antimicrotubule; Central nervous system malignancies; chemoradiotherapy; patupilone; radiotherapy

Indexed keywords

BRAIN TUMORS; CENTRAL NERVOUS SYSTEM MALIGNANCIES; CENTRAL NERVOUS SYSTEMS; CHEMORADIOTHERAPY; DOSE ESCALATION; DOSE LEVELS; DOSE LIMITING TOXICITY; EPOTHILONES; FRACTIONATION SCHEDULES; PHASE I; PHASE II; PULMONARY HEMORRHAGE; RADIATION DOSE; RECURRENT GLIOMAS; RENAL FAILURE; RESPONSE RATE;

PULMONARY DISEASES; RADIOTHERAPY;

TOXICITY;

EPOTHILONE B; STEROID;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTROCYTOMA; BRAIN METASTASIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DYSPNEA; FAILURE TO THRIVE; FATIGUE; FEMALE; FEVER; GLIOMA; GLIOSARCOMA; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY FAILURE; LEUKOPENIA; LIVER FUNCTION TEST; LUNG HEMORRHAGE; MALE; MAXIMUM TOLERATED DOSE; MENINGIOMA; NAUSEA; NEUROBLASTOMA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECOMMENDED DRUG DOSE; SEIZURE; SIDE EFFECT; STEREOTACTIC BODY RADIATION THERAPY; STOMATITIS; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; EPOTHILONES; FEMALE; GLIOMA; HEMORRHAGE; HUMANS; LUNG DISEASES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PNEUMONIA; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; TUBULIN MODULATORS; YOUNG ADULT;

EID: 77953561380     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.06.050     Document Type: Article

References (33)

1. Rowinsky E.K., Onetto N., Canetta R.M., et al. Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 19 (1992) 646-662
2. Donehower R.C., and Rowinsky E.K. An overview of experience with Taxol (paclitaxel) in the U.S.A. Cancer Treat Rev 19 Suppl. C (1993) 63-78
3. Geard C.R., Jones J.M., and Schiff P.B. Taxol and radiation. J Natl Cancer Inst Monogr 15 (1993) 89-94
4. Hei T.K., Piao C.Q., Geard C.R., et al. Taxol and ionizing radiation: interaction and mechanisms. Int J Radiat Oncol Biol Phys 29 (1994) 267-271
5. Liebmann J., Cook J.A., Fisher J., et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86 (1994) 441-446
6. Milas L., Hunter N.R., Kurdoglu B., et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother Pharmacol 35 (1995) 297-303
7. Choy H., Rodriguez F.F., Koester S., et al. Investigation of taxol as a potential radiation sensitizer. Cancer 71 (1993) 3774-3778
8. Choy H., and Browne M.J. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol 22 (1995) 70-74
9. Tishler R.B., Schiff P.B., Geard C.R., et al. Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22 (1992) 613-617
10. Tishler R.B., Geard C.R., Hall E.J., et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52 (1992) 3495-3497
11. Akerley W., and Choy H. Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. Lung Cancer 12 Suppl. 2 (1995) S107-S115
12. Choy H., Yee L., and Cole B.F. Combined-modality therapy for advanced non-small cell lung cancer: Paclitaxel and thoracic irradiation. Semin Oncol 22 (1995) 38-44
13. Choy H., Akerley W., Safran H., et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12 (1994) 2682-2686
14. Glantz M.J., Choy H., Kearns C.M., et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 14 (1996) 600-609
15. Blanke C.D., Choy H., Teng M., et al. Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Semin Radiat Oncol 9 (1999) 43-52
16. Kim J.C., Kim J.S., Saha D., et al. Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells. Radiother Oncol 68 (2003) 305-313
17. Hofstetter B., Vuong V., Broggini-Tenzer A., et al. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res 11 (2005) 1588-1596
18. O'Reilly T., Wartmann M., Brueggen J., et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 62 (2008) 1045-1054
19. McSheehy P, Allegrini P, Becquet M, et al. Patupilone, the novel microtubule stabilizer, inhibits growth of intra-cranial human lung tumors in athymic mice [Abstract]. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, April 1-5, 2006, Washington, DC. Philadelphia: AACR, 2006.
20. Ferretti S, Becquet M, O'Reilly T, et al. Patupilone (EPO906) inhibits growth of human NSCLC tumors and subsequent brain metastases and extends survival: Comparison with other monotherapies [Abstract]. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007, Los Angeles, CA. Philadelphia: AACR, 2007.
21. Forster M., Kaye S., Oza A., et al. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin Cancer Res 13 (2007) 4178-4184
22. Vansteenkiste J., Lara Jr. P.N., Le Chevalier T., et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 25 (2007) 3448-3455
23. Denduluri N., Low J.A., Lee J.J., et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 25 (2007) 3421-3427
24. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 (1991) 109-122
25. Glantz M.J., Choy H., Kearns C.M., et al. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 87 (1995) 1077-1081
26. Heimans J.J., Vermorken J.B., Wolbers J.G., et al. Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol 5 (1994) 951-953
27. O'Neill V, Calvert, P. A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, to patients with advanced solid tumors. Proc Am Soc Clin Oncol 19:2000 (abstr 829).
28. Rubin E., Siu L., Beers S., et al. A phase I and pharmacologic trial of weekly epothilone B in patients with advanced malignancies. Proc Am Soc Clin Oncol 20 (2001) 68a
29. Geard C.R., and Jones J.M. Radiation and taxol effects on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 29 (1994) 565-569
30. Liebmann J., Cook J.A., Fisher J., et al. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol). Int J Radiat Oncol Biol Phys 29 (1994) 559-564
31. Milas L., Hunter N., Mason K.A., et al. Tumor reoxygenation as a mechanism of Taxol-induced enhancement of tumor radioresponse. Acta Oncol 34 (1995) 409-412
32. Chang S.M., Kuhn J.G., Rizzo J., et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report. J Clin Oncol 16 (1998) 2188-2194
33. Chamberlain M.C., and Kormanik P. Salvage chemotherapy with Taxol for recurrent anaplastic astrocytomas. J Neurooncol 43 (1999) 71-78